Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PAPSS1
REST API REST API
Homo sapiens
PAPSS1 is differentially expressed in 272 experiments: 112 organism parts: liver, hypothalamus, ... (110 more);, 205 disease states: normal, Parkinson's disease, ... (203 more);, 79 cell types 379 cell lines 32 compound treatments and 62 other conditions.
Synonyms PAPSS, ATPSK1
Orthologs Papss1 (Rattus norvegicus)   Papss1 (Mus musculus)   F7BBM4_CIOIN (Ciona intestinalis)   Q3T0J0_BOVIN (Bos taurus)   E1C8P2_CHICK (Gallus gallus)   papss1 (Danio rerio)   MET14 (Saccharomyces cerevisiae)   Papss (Drosophila melanogaster)   papss1 (Xenopus laevis)   ENSBTAG00000045655 (Bos taurus)   PAPSS1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, sulfate assimilation, adenylylsulfate kinase activity, ATP binding, transferase activity, transferring phosphorus-containing groups, sulfate adenylyltransferase (ATP) activity, nucleotide binding, kinase activity, nucleotidyltransferase activity, xenobiotic metabolic process, 3'-phosphoadenosine 5'-phosphosulfate metabolic process, skeletal system development, 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process
InterPro Term APS_kinase_C, Sulphate_adenylyltransferase
UniProt Accession Q4W5H3, Q4W5F0, O43252, Q6IAX6
Search EB-eye ENSG00000138801
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-5823, E-GEOD-3529
HCC2157
2
E-MTAB-37, E-MTAB-62
MDA-MB-231
2
E-GEOD-5823, E-TABM-420
SW480
2
E-MEXP-1014, E-GEOD-2509
T84
2
E-GEOD-1474, E-MTAB-37
SK-N-AS
1
E-MTAB-62
373 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-360, ... (39 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
macrophage
1
2
E-GEOD-22373, E-GEOD-3982, E-GEOD-360
spermatocyte
1
E-TABM-130
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (54 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-GEOD-2514, E-MTAB-37, E-MTAB-62
neuroblastoma
2
E-MTAB-62, E-MTAB-37
cervical carcinoma
2
E-MEXP-1331, E-MTAB-62
control
2
E-GEOD-8121, E-GEOD-20168
septic shock
2
E-GEOD-8121, E-GEOD-9692
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
199 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-TABM-782, ... (23 experiments)

Factor Value U/D Experiments
granulocyte-colony stimulating factor
1
E-GEOD-7400
phenol
1
E-GEOD-6907
unknown
1
E-GEOD-7307
TTA
1
E-MEXP-2590
baseline sevoflurane
1
E-GEOD-4386
actinomycin D
1
E-GEOD-6400
26 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-5372, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-MEXP-2359, E-GEOD-2666

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-1561, E-GEOD-2509, E-GEOD-21138

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-22593, E-GEOD-2292, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-MEXP-1446, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (35 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-12293, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.36 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM